{
  "id": 11090360,
  "title": "Samsung Biologics Hunts CDMO Deals Across Four Countries",
  "url": "https://urgent.news/2026/10/01/samsung-biologics-hunts-cdmo-deals-across-four-countries",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-01T02:56:52.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=278026"
  },
  "original_language": "en",
  "account": "Samsung Biologics is set to participate in a series of global events spanning Japan, Italy, the United States, and Korea throughout October. This initiative aims to reinforce the company's status as a leading global biopharmaceutical entity based on its three-pronged expansion strategy: production capacity, business portfolio, and global presence.\n\nFirstly, Samsung Biologics will take part in BioJapan 2026, Asia's biggest exhibition, held in Yokohama, Japan from October 7th to 9th. The company's fourth consecutive appearance at the event will see it showcase an exclusive booth and concentrate on enhancing its leadership within the Asia-Pacific region. Executive Vice President James Choi will deliver a presentation on integrated contract development and manufacturing organization (CDMO) services, while Professional Yeonjung Choi will reveal research advancements in optimizing antibody-drug conjugate (ADC) processes via computational fluid dynamics (CFD).\n\nThe firm will also maintain its focus on the European market. At CPHI Milan 2026, an exclusive booth will be set up at CPHI Milan 2026, a gathering in Milan, Italy from October 6th to 8th. Samsung Biologics aims to engage in business discussions with leading pharmaceutical firms and prospects, presenting its CMO capabilities, global production sites, and next-generation multi-modality technology.\n\nIn the United States, Samsung Biologics will highlight its expertise in the emerging ADC sector, viewed as a promising anti-cancer technology. Participation in World ADC San Diego, taking place in San Diego from October 12th to 15th, will involve both presentation sessions and poster presentations. Team Leader Marc Studer will discuss the triumphs in ADC GMP production ramp-up, while Group Leader Jina Kim and Professional Segyu Oh will share insights on research related to bispecific ADCs and patient-derived organoids.\n\nThe concluding leg of the relay will be Bioplus-Interphex Korea 2026 (BIX) in Seoul from October 28th to 30th. Vice President Taehee Lee will lead a discussion on bispecific and multispecific antibody development strategies, aiming to connect with both domestic and international industry officials. Through its involvement in this global event series, Samsung Biologics intends to reinforce its comprehensive End-to-End services, encompassing research, development, and production, alongside the company's position as the world's largest producer.",
  "summary": "Samsung Biologics will participate in a global relay of events connecting Japan, Italy, the United States, and Korea throughout the month of October. This move is aimed at solidifying its position as a global top-tier bio company based on its 'three-pillar expansion' strategy of production capacity,",
  "key_points": [
    "Samsung Biologics to attend BioJapan 2026 in Yokohama, Japan from Oct 7-9",
    "Company to showcase exclusive booth, focus on Asia-Pacific leadership",
    "Executive Vice President James Choi to present on integrated CDMO services"
  ],
  "editors_take": "By participating in a series of global events, Samsung Biologics aims to strengthen its position as a leading biopharmaceutical entity by showcasing its CDMO services, production capabilities, and global presence.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}